Therapy based on synthetic lethality in SWI / SNF complex-dysfunction cancer

Abstract

The present disclosure provides a pharmaceutical composition for treating and / or preventing SWI / SNF complex-dysfunction cancer. More specifically, according to the present disclosure, a compound represented by formulae (1) to (23) (the formulae are as set forth in the specification) or a pharmaceutically acceptable salt thereof can have a therapeutic and / or prophylactic effect on SWI / SNF complex-dysfunction cancer. A pharmaceutical composition, which is for treating and / or preventing cancer and contains an CBP / P300 inhibitor, can be provided. The cancer may be SWI / SNF complex-dysfunction cancer. The SWI / SNF complex-dysfunction cancer may be BAF complex-dysfunction cancer. The BAF complex-dysfunction cancer may be SMARC-deficient cancer, ARID-deficient cancer, or SS18-SSX fusion cancer. The SMARC-deficient cancer may be SMARCB1-deficient cancer, SMARCA2-deficient cancer, SMARCA4-deficient cancer, or SMARCA2 / A4-deficient cancer.